In our continuing series on role the environment plays in thoracic oncology, Dr. Roselle De Guzman outlines the risks posed by our changing climate and the potential benefits of taking a proactive approach to reduce those risks. Read more
Dr. Leticia Nogueira says the time has come for the lung cancer community to champion environmentally responsible practices that help mitigate cancer risks and outcomes. Read more
Durvalumab is recommended for approval in the EU, Health Canada approves pembrolizumab, and the US FDA grants priority review to datopotamab deruxtecan. Read more
The American Cancer Society’s Dr. Leticia Nogueira says lung cancer epitomizes the severe and inescapable threats climate change pose to cancer control activities. Read more
The US FDA grants fast track designation to treat KRAS G12C-mutant metastatic NSCLC and China’s NMPA approves taletrectinib for advanced ROS1-positive NSCLC. Read more
Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the importance of biomarkers for guiding optimal treatment. Read more
The combination treatment is the first and only regimen to show a survival benefit that surpasses the current standard of care for EGFR-mutated lung cancer. Read more
A new genetics study aims to collect data from 10,000 participants diagnosed with lung cancer to improve future outcomes and enhance research. Read more
FDA issues draft guidance on the use of AI for biological and drug product submissions, China’s NMPA grants priority review for the combination of savolitinib and osimertinib, and nivolumab and hyaluronidase-nvhy receive FDA approval for subcutaneous injection. Read more
During the opening plenary session at the 2024 Asia Conference on Lung Cancer, experts offered their perspectives on clinical trials, combination therapies, and research initiatives. Read more